Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Liraglutide and Renal Outcomes in Type 2 Diabetes.

Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators.

N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011.

2.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators.

N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.

3.

In antibody-positive first-degree relatives of patients with type 1 diabetes, HLA-A*24 and HLA-B*18, but not HLA-B*39, are predictors of impending diabetes with distinct HLA-DQ interactions.

Mbunwe E, Van der Auwera BJ, Weets I, Van Crombrugge P, Crenier L, Coeckelberghs M, Seret N, Decochez K, Vandemeulebroucke E, Gillard P, Keymeulen B, van Schravendijk C, Wenzlau JM, Hutton JC, Pipeleers DG, Gorus FK; Belgian Diabetes Registry.

Diabetologia. 2013 Sep;56(9):1964-70. doi: 10.1007/s00125-013-2951-8. Epub 2013 May 28.

4.

HLA-A*24 is an independent predictor of 5-year progression to diabetes in autoantibody-positive first-degree relatives of type 1 diabetic patients.

Mbunwe E, Van der Auwera BJ, Vermeulen I, Demeester S, Van Dalem A, Balti EV, Van Aken S, Derdelinckx L, Dorchy H, De Schepper J, van Schravendijk C, Wenzlau JM, Hutton JC, Pipeleers D, Weets I, Gorus FK; Belgian Diabetes Registry.

Diabetes. 2013 Apr;62(4):1345-50. doi: 10.2337/db12-0747. Epub 2012 Nov 16.

5.

Mendelian randomization study of interleukin-6 in chronic obstructive pulmonary disease.

van Durme YM, Lahousse L, Verhamme KM, Stolk L, Eijgelsheim M, Loth DW, Uitterlinden AG, Breteler MM, Joos GF, Hofman A, Stricker BH, Brusselle GG.

Respiration. 2011;82(6):530-8. doi: 10.1159/000332336. Epub 2011 Oct 11.

6.

Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: a retrospective observational study.

Coeman M, van Durme Y, Bauters F, Deschepper E, Demedts I, Smeets P, Joos G, Brusselle G.

Ther Adv Respir Dis. 2011 Dec;5(6):377-86. doi: 10.1177/1753465811406771. Epub 2011 Sep 2.

PMID:
21890536
7.

MicroRNA expression in induced sputum of smokers and patients with chronic obstructive pulmonary disease.

Van Pottelberge GR, Mestdagh P, Bracke KR, Thas O, van Durme YM, Joos GF, Vandesompele J, Brusselle GG.

Am J Respir Crit Care Med. 2011 Apr 1;183(7):898-906. doi: 10.1164/rccm.201002-0304OC. Epub 2010 Oct 29.

PMID:
21037022
8.

Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function.

Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR, Marciante KD, Franceschini N, van Durme YM, Chen TH, Barr RG, Schabath MB, Couper DJ, Brusselle GG, Psaty BM, van Duijn CM, Rotter JI, Uitterlinden AG, Hofman A, Punjabi NM, Rivadeneira F, Morrison AC, Enright PL, North KE, Heckbert SR, Lumley T, Stricker BH, O'Connor GT, London SJ.

Nat Genet. 2010 Jan;42(1):45-52. doi: 10.1038/ng.500. Epub 2009 Dec 13.

9.

Hedgehog-interacting protein is a COPD susceptibility gene: the Rotterdam Study.

Van Durme YM, Eijgelsheim M, Joos GF, Hofman A, Uitterlinden AG, Brusselle GG, Stricker BH.

Eur Respir J. 2010 Jul;36(1):89-95. doi: 10.1183/09031936.00129509. Epub 2009 Dec 8.

10.

Decreased FOXP3 protein expression in patients with asthma.

Provoost S, Maes T, van Durme YM, Gevaert P, Bachert C, Schmidt-Weber CB, Brusselle GG, Joos GF, Tournoy KG.

Allergy. 2009 Oct;64(10):1539-46. doi: 10.1111/j.1398-9995.2009.02056.x. Epub 2009 Apr 9.

PMID:
19392991
11.

Prevalence, incidence, and lifetime risk for the development of COPD in the elderly: the Rotterdam study.

van Durme YMTA, Verhamme KMC, Stijnen T, van Rooij FJA, Van Pottelberge GR, Hofman A, Joos GF, Stricker BHC, Brusselle GG.

Chest. 2009 Feb;135(2):368-377. doi: 10.1378/chest.08-0684.

PMID:
19201711
12.

C-reactive protein levels, haplotypes, and the risk of incident chronic obstructive pulmonary disease.

van Durme YM, Verhamme KM, Aarnoudse AJ, Van Pottelberge GR, Hofman A, Witteman JC, Joos GF, Brusselle GG, Stricker BH.

Am J Respir Crit Care Med. 2009 Mar 1;179(5):375-82. doi: 10.1164/rccm.200810-1540OC. Epub 2008 Dec 18.

PMID:
19096002
13.

A case-control study of the relation between plasma selenium and asthma in European populations: a GAL2EN project.

Burney P, Potts J, Makowska J, Kowalski M, Phillips J, Gnatiuc L, Shaheen S, Joos G, Van Cauwenberge P, van Zele T, Verbruggen K, van Durme Y, Derudder I, Wohrl S, Godnic-Cvar J, Salameh B, Skadhauge L, Thomsen G, Zuberbier T, Bergmann KC, Heinzerling L, Renz H, Al-Fakhri N, Kosche B, Hildenberg A, Papadopoulos NG, Xepapadaki P, Zannikos K, Gjomarkaj M, Bruno A, Pace E, Bonini S, Bresciani M, Gramiccioni C, Fokkens W, Weersink EJ, Carlsen KH, Bakkeheim E, Loureiro C, Villanueva CM, Sanjuas C, Zock JP, Lundback B, Janson C.

Allergy. 2008 Jul;63(7):865-71. doi: 10.1111/j.1398-9995.2008.01716.x. Erratum in: Allergy. 2008 Dec;63(12):1647..

PMID:
18588552
14.

The relation between paracetamol use and asthma: a GA2LEN European case-control study.

Shaheen S, Potts J, Gnatiuc L, Makowska J, Kowalski ML, Joos G, van Zele T, van Durme Y, De Rudder I, Wöhrl S, Godnic-Cvar J, Skadhauge L, Thomsen G, Zuberbier T, Bergmann KC, Heinzerling L, Gjomarkaj M, Bruno A, Pace E, Bonini S, Fokkens W, Weersink EJ, Loureiro C, Todo-Bom A, Villanueva CM, Sanjuas C, Zock JP, Janson C, Burney P; Selenium and Asthma Research Integration project; GA2LEN.

Eur Respir J. 2008 Nov;32(5):1231-6. doi: 10.1183/09031936.00039208. Epub 2008 Jun 25.

Supplemental Content

Loading ...
Support Center